AMELIA TECHNOLOGIES LLC

Washington, DC · Medtech · Private

UValidate—a high-throughput cell-based screening platform that tests UV filter safety and efficacy by measuring DNA damage, reactive oxygen species, and micronuclei in cultured keratinocytes and melan

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Medtech
Headquarters: Washington, DC
Total capital: $12.4M

Federal grants: $12.4M; 20 awards · 2018–2026; Rank in peer group#10 of 15
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Jun 2026Federal grantHealth and Human S · Phase II · EcoWell: Smart Incubation Technology for Next-Generation Environmental Science Labs$1M
Aug 2025Federal grantHealth and Human S · Phase I · Using microsphere technology for the electrochemical measurement of genotoxicity.$303K
Mar 2024Federal grantHealth and Human S · Phase II · EcoWell- A planet in a plate.$274K
Aug 2023Federal grantHealth and Human S · Phase II · Development of the UValidate platform for the profiling of topically applied chemical agents.$864K
Jun 2023Federal grantHealth and Human S · Phase II · Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variability$840K
Sep 2022Federal grantHealth and Human S · Phase II · Development of the UValidate platform for the profiling of topically applied chemical agents.$809K
Sep 2022Federal grantHealth and Human S · Phase II · Development of the UValidate platform for the profiling of topically applied chemical agents.$1.7M

Show 13 earlier federal awards

Jul 2022Federal grantHealth and Human S · Phase II · Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variability$840K
May 2021Federal grantHealth and Human S · Phase I · Optimization of the UValidate platform to measure genotoxicity associated with current problematic UV chemical blockers$51K
Feb 2021Federal grantHealth and Human S · Phase II · Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variability$250K
Sep 2020Federal grantHealth and Human S · Phase I · The development of FastMycoâ¢ : A novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination .$274K
Jul 2020Federal grantHealth and Human S · Phase I · The development of FastMycoâ¢ : A novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination .$274K
May 2020Federal grantHealth and Human S · Phase I · Optimization of the UValidate platform to measure genotoxicity associated with current problematic UV chemical blockers$247K
Apr 2020Federal grantHealth and Human S · Phase I · Optimization of the UValidate platform to measure genotoxicity associated with current problematic UV chemical blockers$195K
Sep 2019Federal grantHealth and Human S · Phase II · Expansion of Immuno-CometChip Platform$8K
Apr 2019Federal grantHealth and Human S · Phase II · Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing$827K
Apr 2019Federal grantHealth and Human S · Phase II · Novel genotoxicity assay incorporating the toxicogenomics biomarker TGx-28.65 with a direct digital counting$655K
May 2018Federal grantHealth and Human S · Phase II · Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing$666K
May 2018Federal grantHealth and Human S · Phase II · Novel genotoxicity assay incorporating the toxicogenomics biomarker TGx-28.65 with a direct digital counting$840K
May 2018Federal grantHealth and Human S · Phase II · Novel genotoxicity assay incorporating the toxicogenomics biomarker TGx-28.65 with a direct digital counting$1.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 15 peers

Line = median

Medtech · Platform

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

TREVIGEN, INC.Shares a founder: JAY GEORGE
Mentor on the Go LLCSimilar federal contract value in Medtech · null in contracts
KUBANDA CRYOTHERAPY, INC.Similar federal contract value in Medtech · null in contracts
PREVENTA MEDICAL CORPORATIONSimilar federal contract value in Medtech · null in contracts
ABILITY INTERACTIVE LLCSimilar federal contract value in Medtech · null in contracts
ICBiomeSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.